The main treatment of cancer is still surgery, but, for some cancers, medical treatment offers a important alternative. In Basal Cell Carcinoma (BCC), the use of imiquimod for superficial BCC is well stablished and approved in many countries. Recently, in Australia, another molecule, vismodegib, has been approved for the treatment of BCC. In this case, the cost and side effects of the medication limits its use to advance BCC that can not be treated with radiotherapy or surgery. A/Prof Pablo Fernandez-Peñas reviewed the hedgehog pathway (that it’s mutated in most (90%) of BCC) and the use of vismodegib (an inhibitor of this pathway) in a recent meeting at the Skin & Cancer Foundation Australia. Clinical results, adverse events (mainly muscle spams, taste disturbances and alopecia) and strategies to manage these events were discussed. The criteria for prescribing vismodegib in Australia, and the challenges ahead were other topics addressed. The Oncodermatology Unit of the Department of Dermatology at Westmead Hospital has good experience in treating patient with vismodegib and runs a specialised clinic for these patients. Our Unit is happy to help patients that may need treatment with vismodegib. If you are a patient, discuss this approach with your doctor. And if you are a prescriber, do not hesitate to contact us for any query.
Westmead Dermatology
Striving towards disease-free skin
